Prognostic impact of histopathological features and serum inflammatory markers in patients with gastric cancer undergoing neoadjuvant therapy

Table 3 Multivariate analysis of overall survival by patient and tumor characteristics, n (%)

Population characteristics	Alive, 118 (66.7)	Dead, 59 (33.3)	P value	Univariate analysis of OS, months	P value	Multivariate analysis, P value
Age, years			0.33		0.14
< 65	67 (56.8)	29 (49.2)		NA
≥ 65	51 (43.2)	27 (50.8)		33.6
Gender			0.35		0.12
Male	86 (72.9)	39 (66.1)		26.9
Female	32 (27.1)	20 (33.9)		45.9
ECOG PS			0.06		0.21
0	77 (65.3)	30 (50.8)		NA
1	41 (34.7)	29 (49.2)		29.0
Body mass index			0.003		0.04
≥ 25	68 (59.1)	21 (35.6)		NA
< 25	47 (40.9)	38 (64.4)		27.6
Histological type			< 0.001		< 0.001
Adeno	104 (88.1)	37 (62.7)		45.9
Signet ring cell	14 (11.9)	22 (37.3)		21.5
c-T stage			< 0001		0.001
1-2	28 (23.7)	1 (1.7)		NA
3-4	90 (76.3)	58 (98.3)		28.7
c-N stage			0.06		0.07
Negative	20 (16.9)	4 (6.8)		NA
Positive	98 (83.1)	55 (93.2)		33.4
c-stage			< 0.001		< 0.001
1-2	42 (35.6)	5 (8.5)		NA
3	76 (64.4)	54 (91.5)		27.6
Grade			0.001		< 0.001
I-II	68 (57.6)	19 (32.2)		NA
III	50 (42.4)	40 (67.8)		23.6
HER-2 status			0.990		0.850
Negative	105 (94.6)	53 (94.6)		36.0
Positive	6 (5.4)	3 (5.4)		15.7
MSI			0.34		0.340
Low	96 (89.7)	46 (95.8)		37.3
High	11 (10.3)	2 (4.2)		NA
pT stage			< 0.001		< 0.001
0-2	55 (46.6)	9 (15.3)		NA
3-4	63 (53.4)	50 (84.7)		26.9
pN stage			< 0.001		0.001
N0-1	84 (71.2)	16 (27.1)		NA
N2-3	34 (28.8)	43 (72.9)		21.5
yp stage			< 0.001		< 0.001
0-1	47 (39.8)	4 (6.8)		NA
2-3	71 (60.2)	55 (93.2)		26.9
Lymphovascular invasion			< 0.001		< 0.001	HR: 3.68, P < 0.003, CI: 1.536-8.829
No	63 (53.4)	7 (11.9)		NA
Yes	55 (46.6)	52 (88.1)		26.3
Perineural invasion			< 0.001		< 0.001
No	74 (62.7)	16 (27.1)		NA
Yes	44 (37.3)	43 (72.9)		26.3
Surgery			< 0.001		< 0.001	HR: 2.37, P = 0.01, CI: 1.219-4.634
R0	112 (94.9)	45 (76.3)		37.3
R1	6 (5.1)	14 (23.7)		14.8
Regression score			< 0.001		0.001
1	38 (32.2)	4 (6.8)		NA
2-3	80 (67.8)	55 (93.2)		27.6
Adjuvant			< 0.001		< 0.001	HR: 3.99, P < 0.001, CI: 2.253-7.097
Yes	110 (93.2)	40 (67.8)		NA
No	8 (6.8)	19 (32.2)		11.0
Postoperative radiotherapy			0.03		0.14
No	35 (29.7)	27 (45.8)		NA
Yes	83 (70.3)	32 (54.2)		26.3
NLR (median = 2.06)			0.27		0.33
Low	60 (50.8)	24 (42.1)		37.3
High	58 (49.2)	33 (57.9)		33.4
PLR (median = 128.4)			0.04		0.05
Low	65 (55.1)	22 (38.6)		NA
High	53 (44.9)	35 (61.4)		29.0
Anemia, < 12 g/dL			0.44		0.35
No	45 (38.1)	26 (44.1)		27.2
Yes	73 (61.9)	33 (55.9)		36.0
Albumin, 3.5 g/dL			0.001		0.01	HR: 2.50, P = 0.01, CI: 1.198-5.215
High	114 (97.4)	48 (84.2)		45.9
Low	3 (2.6)	9 (15.8)		15.9
CEA			0.85		0.94
< 5 ngr/L	77 (72.0)	36 (70.6)		36.0
> 5 ngr/L	30 (28.0)	15 (29.4)		37.3

OS: Overall survival; HR: Hazard ratio; CI: Confidence interval; ECOG PS: Eastern Cooperative Oncology Group performance status; c-T: Clinic tumor stage; c-N: Clinic lymph node stage; MSI: Microsatellite instability; pT: Pathological tumor stage; pN: Pathological node stage; yp stage: Post neoadjuvant therapy stage; NLR: Neutrophil-to-lymphocyte count; PLR: Platelet-to-lymphocyte count; CEA: Carcinoembryonic antigen; NA: Not available.